Pearl River Capital’s Immunogen Inc IMGN Stock Holding History

Pearl River Capital’s Portfolio IMGN Stock Details IMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-1,372	Closed	-$7K	–	873
2018 Q4	$7K	Buy	+1,372	New	+$8.32K	0.03%	659

Other funds holding IMGN

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Pearl River Capital's IMGN Position: Q1 2019 in Review

Pearl River Capital sold out of Immunogen Inc (IMGN) in Q1 2019, closing a stake of 1,372 shares — an estimated $7K sold.

Pearl River Capital first reported a position in IMGN in Q4 2018 and held it in 1 quarter. The position peaked at $7K in Q4 2018. 212 funds tracked by Wall St. Rank hold IMGN as of Q1 2019.

Pearl River Capital reported no remaining Immunogen Inc position as of Q1 2019 after selling out during the quarter.
Pearl River Capital sold 1,372 Immunogen Inc shares in Q1 2019, an estimated $7K.
Pearl River Capital first reported a position in Immunogen Inc in Q4 2018 and held it in 1 quarter.
Pearl River Capital's Immunogen Inc position peaked at $7K in Q4 2018.
212 funds tracked by Wall St. Rank held Immunogen Inc as of Q1 2019.

Based on Pearl River Capital's 13F filing for Q1 2019, filed 2 May 2019.